Provided By GlobeNewswire
Last update: Nov 10, 2025
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval
NASDAQ:CINGW (11/14/2025, 8:00:00 PM)
0.0312
0 (-2.5%)
3.49
+0.16 (+4.8%)
Find more stocks in the Stock Screener


